Two Years of PRIME

The EMA recently released it's two-year report on the PRIority MEdicines (PRIME) scheme[1]. A positive outlook and good to see that early interactions with bodies such as the Pharmacovigilance Risk Assessment Committee (PRAC), is being viewed positively by applicants:

Drive Phase PV is a pharmacovigilance consultancy and provider of pharmacovigilance services, supporting patient safety throughout the life-cycle of our clients' products. Whether via SOP development or provision of training, we deliver a tailored packaged to seamlessly fit to your company structure and strategy.

1. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2018/05/WC500248828.pdf